Business
Clinical Utility Study
Clinical Utility Study.
About this update from Renalytix Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 7571U\n Renalytix AI PLC\n 08 April 2021\n \n \n \n \n \n \n \n \n \n \n Renalytix AI plc\n \n \n \n (\"RenalytixAI\" or the \"Company\")\n \n \n \n \n \n \n Clinical Utility Study Demonstrates Primary Care Physicians Highly Likely to Order KidneyIntelX to Inform Care Decisions \n \n \n \n \n \n Value of KidneyIntelX Testing Demonstrated by Data from 401 Physician Study Presented at National Kidney Foundation 2021 Spring Clinical Meetings \n \n \n \n \n \n \n NEW YORK, April 8, 2021\n \n - \n \n Renalytix AI plc\n \n (LSE: RENX) (NASDAQ: RNLX) announces findings presented in a Late-Breaking presentation at the \n \n National Kidney Foundation's 2021 Spring Clinical Meetings (NKF SCM21)\n \n titled \n \n Clinical Utility of a New Prognostic Test to Predict the Risk of Kidney Function Decline in Diabetic Kidney Disease Patients\n \n . Results support that \n \n KidneyIntelX\n \n may be widely adopted by primary care physicians (PCPs) and that the easy-to-understand risk score and recommended care path on the report could help improve care for patients at high risk for progressive kidney function decline or failure. The findings from this study are significant for clinicians, health systems, payers and patients in understanding the value of KidneyIntelX testing in large scale adult diabetic kidney disease (DKD) populations. \n \n \n \n \n \n \"Clear and objective utility evidence like these results presented at the NKF Spring Clinical Meeting this week are critical for evaluating the value of innovative new approaches for CKD assessment,\" said Elizabeth Montgomery, Vice-President, Learning Strategies and Primary Care Programs at the National Kidney Foundation. \"This is important evidence for clinicians, decision-makers and payers as it illustrates the benefits of focusing on preserving kidney health in the earliest stages of the disease when new therapeutics, patient engagement and specialist referral have the potential to delay or prevent progression. The results of the study involving 401 primary care physicians show what can be possible for improving outcomes and quality of life for patients who otherwise are likely to progress to end-stage kidney disease, dialysis or transplant,\" commented Ms. Montgomery.\n \n \n \n \n \n In the s...